08:33:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-15 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-06-03 Extra Bolagsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-04-17 X-dag ordinarie utdelning PEG 0.00 DKK
2024-04-16 Årsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-11-02 Extra Bolagsstämma 2023
2023-08-16 Kvartalsrapport 2023-Q2
2023-04-26 X-dag ordinarie utdelning PEG 0.00 DKK
2023-04-25 Årsstämma 2023
2023-03-31 Bokslutskommuniké 2022
2022-10-27 Extra Bolagsstämma 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-26 X-dag ordinarie utdelning PEG 0.00 DKK
2022-04-25 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2022-01-21 Bokslutskommuniké 2021
2021-11-10 Extra Bolagsstämma 2021
2021-08-30 Kvartalsrapport 2021-Q2
2021-05-03 X-dag ordinarie utdelning PEG 0.00 DKK
2021-04-29 Årsstämma 2021
2020-08-24 Kvartalsrapport 2020-Q2
2020-04-28 X-dag ordinarie utdelning PEG 0.00 DKK
2020-04-27 Årsstämma 2020
2020-03-30 Bokslutskommuniké 2019
2019-11-01 Split PEG 10:1
2019-08-23 Kvartalsrapport 2019-Q2
2019-04-29 X-dag ordinarie utdelning PEG 0.00 DKK
2019-04-26 Årsstämma 2019
2019-03-29 Bokslutskommuniké 2018
2019-02-26 Extra Bolagsstämma 2019
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2018-04-30 Årsstämma 2018
2018-04-06 Bokslutskommuniké 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2017-04-28 Årsstämma 2017
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-05-02 X-dag ordinarie utdelning PEG 0.00 DKK
2016-04-29 Årsstämma 2016
2016-03-31 Bokslutskommuniké 2015
2016-02-24 Split PEG 1:10
2016-02-18 Extra Bolagsstämma 2016
2015-10-21 Kvartalsrapport 2015-Q3
2015-07-15 Kvartalsrapport 2015-Q2
2015-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2015-04-30 Årsstämma 2015
2015-04-14 Kvartalsrapport 2015-Q1
2015-03-31 Bokslutskommuniké 2014
2015-02-02 Extra Bolagsstämma 2015
2014-12-22 Extra Bolagsstämma 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-15 Kvartalsrapport 2014-Q2
2014-05-09 Kvartalsrapport 2014-Q1
2014-04-30 Årsstämma 2014
2014-04-01 X-dag ordinarie utdelning PEG 0.00 DKK
2014-03-31 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-16 Kvartalsrapport 2013-Q2
2013-05-07 Kvartalsrapport 2013-Q1
2013-04-30 Årsstämma 2013
2013-04-01 X-dag ordinarie utdelning PEG 0.00 DKK
2013-03-29 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-17 Kvartalsrapport 2012-Q2
2012-05-07 Kvartalsrapport 2012-Q1
2012-05-01 X-dag ordinarie utdelning PEG 0.00 DKK
2012-04-30 Årsstämma 2012
2012-03-30 Bokslutskommuniké 2011
2011-11-04 Extra Bolagsstämma 2011
2011-05-02 X-dag ordinarie utdelning PEG 0.00 DKK
2011-04-29 Årsstämma 2011
2010-05-03 X-dag ordinarie utdelning PEG 0.00 DKK

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Pharma Equity Group utvecklar nya läkemedel för lokal behandling av allvarliga och livshotande inflammatoriska sjukdomar för vilka det för närvarande inte finns någon adekvat behandling. Bolaget använder ompositionering av befintliga läkemedel och tar läkemedelskandidater till ett kliniskt fas III-stadium, varefter de överlämnas till en strategisk partner som kommer att slutföra utvecklingen av produkterna och föra ut dem på marknaden, antingen självständigt eller i samarbete med bolaget.
2024-03-05 10:11:05

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

05 March 2024

Company Announcement No. 06

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) about the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Today's announcement signifies a significant milestone as the EPO has approved EP patent No. 3145533, encompassing Reponex' innovative treatment method. This method consists of topically applying a hydrogel containing granulocyte-macrophage colony-stimulating factor (GM-CSF), sucralfate, and hyaluronan to accelerate wound healing. The combination helps stimulating the proliferation of cells related to the healing process and tissue regeneration.

"We are very pleased that the EPO has now approved the patent application for our drug candidate RNX-022, allowing us to protect our product in such a crucial commercial domain," says Thomas Kaas Selsø, CEO of Pharma Equity Group A/S.

Wound healing represents a significant challenge for many individuals, necessitating the development of enhanced treatment methodologies to address the complexities and improve patient outcomes effectively. According to Grand View Research, the global wound treatment market was valued at USD 21.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 4.15% from 2023 to 2030.

The patent is valid until 2035. With the attainment of full Supplementary Protection Certificate (SPC) extension, the validity will extend until 2040.

For further information, please contact:
Thomas Kaas Selsø, CEO
Phone: +45 4022 2114
E-mail: tks@pharmaequitygroup.com

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.